Revamped Adherence Strategies Could Help Reduce Revenue Loss

Eileen Oldfield, Associate Editor
Published Online: Friday, January 4, 2013
Follow Pharmacy_Times:
Medication nonadherence leads to billion dollar losses for pharmaceutical companies, a report indicates.

Nonadherence to medication for chronic conditions results in an estimated $188 billion revenue loss per year for the pharmaceutical industry, according to a report produced by Capgemini Consulting and HealthPrize Technologies. The loss amounts to 59% of total pharmaceutical revenue in the United States and can be extrapolated to an estimated loss of $564 billion in global pharmaceutical revenues.
 
The report authors based their findings on adherence data in published medical studies from 2003 to 2012 that included refill data from pharmacy claims. They did not focus on medication for non-chronic conditions, due to lack of adherence data on non-chronic conditions. In addition, most studies did not account for refills beyond the first refill, despite a propensity for reductions in adherence after 3 months of therapy and nonadherence to long-term or lifelong therapy.
 
Medication classes with the greatest revenue loss due to nonadherence were respiratory agents, antidepressants, anti-ulcerants, antidiabetics, and antipsychotics, according to the report.
 
In a survey of pharmaceutical executives conducted prior to the report, all respondents said the industry bears some responsibility for improving adherence. In addition, 80% of respondents rated medication adherence as a high priority or the highest priority for their company.
 
“I believe the pharma industry, health care professionals, and payers all bear an equal responsibility for promoting improved adherence to medication,” said a respondent quoted in the report.
 
“It is the biggest issue affecting positive treatment outcomes for most chronic therapies,” another respondent is quoted as saying.
 
The report authors noted that pharmaceutical companies’ existing strategies—including medication adherence teams that recommend traditional or isolated strategies—do not address the problem of nonadherence at its roots and are often inadequate for addressing the problem.
 
The pharmacist’s position as a frequently visited and trusted health professional offers a unique opportunity for adherence management, Pharmacy Times Editor-in-Chief Fred Eckel has noted.
 
In addition, several studies have demonstrated the value of pharmacist counseling in both medication initiation and adherence. A study published in the March 15, 2012, edition of the American Journal of Health-System Pharmacy found that patients diagnosed with osteoporosis were more likely to initiate therapy after a pharmacist consult. Meanwhile, a program in which pharmacists monitored and counseled hypertension patients led to better blood pressure control compared with usual care, according to a study presented at the American Heart Association’s Quality of Care and Outcomes Research Scientific Sessions 2012.

Related Articles
Americans make many assumptions about aging, and health care providers are no exception.
COPD patients must clear major hurdles before and after initiating nebulizer use.
Pharmacist-driven drug management programs best ensure atrial fibrillation patients adhere to the warfarin alternative, dabigatran (Pradaxa).
David Nau, PhD, RPh, FAPhA, president of Pharmacy Quality Solutions, talks about how Electronic Quality Improvement Platform for Plans and Pharmacies has helped pharmacists.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$